Moffitt researchers develop tool to b... - British Lung Foun...

British Lung Foundation

46,255 members54,583 posts

Moffitt researchers develop tool to better predict treatment course for lung cancer.


Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related death worldwide, two major treatment strategies have emerged: tyrosine kinase inhibitors and immune checkpoint inhibitors. However, choosing the right therapy for a non-small cell lung cancer patient isn't always an easy decision, as biomarkers can change during therapy rendering that treatment ineffective. Moffitt Cancer Center researchers are developing a noninvasive, accurate method to analyze a patient's tumor mutations and biomarkers to determine the best course of treatment.

Nature Communications. Research paper:

1 Reply

Thanks 2greys.

You may also like...